On this World AIDS Day we are filled with both hope and concern.
Hope because significant progress has been made towards universal access. New HIV infections have dropped. Fewer children are born with HIV. And more than 4 million people are on treatment.
Concern because 28 years into the epidemic the virus continues to make inroads into new populations; stigma and discrimination continue to undermine efforts to turn back the epidemic. The violation of human rights of people living with HIV, women and girls, men who have sex with men, injecting drug users and sex workers must end.
UN Secretary-General Ban Ki-moon has called on "all countries to live up to their commitments to enact or enforce legislation outlawing discrimination against people living with HIV and members of vulnerable groups". On this World AIDS Day, let us work urgently to remove punitive laws and practices and put an end to discrimination against and criminalization of people affected by HIV.
On World AIDS Day let us also act on HIV prevention. For every two people put on treatment, five are newly infected. Too often prevention programmes are not reaching those most in need.
We can eliminate mother-to-child transmission of HIV. We can empower young people to protect themselves from HIV. We can stop violence against women and girls. We can protect drug users from becoming infected with HIV. And we can reduce sexual transmission of HIV.
Gains made today are fragile and must be sustained. The economic crisis should not be a reason for reducing investments in health. Economic adjustments must be made through a human rights lens that keeps the focus on those most vulnerable. This is the time to increase rather than decrease funding for AIDS.
AIDS provides a powerful mechanism for creating integrated health, human rights and development programmes. We must take AIDS out of isolation and create a broad social movement that will accelerate progress toward the Millennium Development Goals.
World AIDS Day provides an opportunity for all of us - individuals, communities and political leaders - to take action towards making universal access a reality.
Michel Sidibé, Executive Director of UNAIDS.
Business & Industry
- Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
- Pfizer to acquire Metsera and its next-generation obesity portfolio
- Roche enters into a definitive merger agreement to acquire 89bio
- Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)
- Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain
Research & Development
- Widely prescribed opioid painkiller tramadol not that effective for easing chronic pain
- Microbiome and nanoparticle discoveries hold promise for treating gut pain
- New antibiotic targets IBD - and AI predicted how it would work before scientists could prove it
- Combination of two drugs that fight cardiovascular risk could also help treat the most common liver disease
- The 2025 Nobel Prize in Physiology or Medicine
- Immune cell ‘signatures’ could help guide treatment for critically ill patients
- Meet your worm avatar: How microscopic worms are helping find new drugs for rare diseases
Conferences & Events
- Cohort data from Denmark show real-world evidence of stable protection against HPV-related cervical cancer
- New insights into T and B cells offer hope for autoimmune disease sufferers
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
Regulatory Affairs
- FDA approves first gene therapy for treatment of aromatic L-amino acid decarboxylase deficiency
- FDA approves new treatment for hemophilia A or B
- FDA approves nasal spray influenza vaccine for self- or caregiver-administration
- FDA approves first nasal spray for treatment of anaphylaxis
- FDA approves nonsteroidal treatment for Duchenne muscular dystrophy